CHEMO/Exeltis is very pleased to announce FDA's approval of the Slynd (drosperinone) for prescription use in the United States.
AbbVie receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Monderate to Severe Pain Associated with Endometriosis.
Endoceutics® Receives Health Canada Approval for Intraraosa®. The first innovative drug for the treatment of vulvovaginal atrophy with prasterone.
Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis